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Background: During the five decades since their discovery, filoviruses of four species have caused human he-
morrhagic fever outbreaks: Marburg (MARV) marburgvirus, and Zaire (EBOV), Sudan (SUDV) and Bundybugyo
(BDBV) ebolaviruses. The largest, devastating EBOV epidemic in West Africa in 2014-16, has been followed by
outbreaks of MARV in Uganda, 2017, and EBOV in Democratic Republic of Congo, 2018, emphasizing the need
to develop preparedness to diagnose all filoviruses.
Objectives: The aim of this study was to optimize a new filovirus RT-qPCR to detect all filoviruses, define its
limits of detection (LOD) and perform a field evaluation with outbreak samples.
Study design: A pan-filovirus RT-qPCR targeting the L gene was developed and evaluated within the
EbolaMoDRAD (Ebola virus: modern approaches for developing bedside rapid diagnostics) project. Specificity
and sensitivity were determined and the effect of inactivation and PCR reagents (liquid and lyophilized format)
were tested.
Results: The LODs for the lyophilized pan-filovirus L-RT-qPCR assay were 9.4 copies per PCR reaction for EBOV,
9.9 for MARV, 1151 for SUDV, 65 for BDBV and 289 for Taï Forest virus. The test was set at the Pasteur Institute,
Dakar, Senegal, and 83 Ebola patient samples, with viral load ranging from 5 to 5 million copies of EBOV per
reaction, were screened. The results for the patient samples were in 100% concordance with the reference EBOV-
specific assay.
Discussion: Overall, the assay showed good sensitivity and specificity, covered all filoviruses known to be human
pathogens, performed well both in lyophilized and liquid-phase formats and with EBOV outbreak clinical
samples.
1. Background
Members of marburgvirus and ebolavirus genera in the family
Filoviridae cause highly contagious illnesses with high mortality rate.
There are five established species of ebolavirus: Zaire (EBOV),
Bundibugyo (BDBV), Sudan (SUDV), Taï Forest (TAFV) and Reston
(RESTV) viruses. All five can cause human infections, the first three
have caused Ebola virus disease (EVD) outbreaks, TAFV has been as-
sociated with only one human case, whereas RESTV has been associated
only with asymptomatic human seroconversions. Members of the
Marburgvirus genus, consisting of the Marburg marburgvirus (MARV)
and the Ravn virus (RAVV), also cause severe hemorrhagic fever in
humans [1]. The third genus, Cuevavirus, is represented by the species
Lloviu cuevavirus (LLOV), which hasn’t yet been associated with
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human infections [2]. Filoviruses are thought to be zoonotic, and bats
are considered the likely reservoirs of these viruses [3]. The Egyptian
fruit bat, Rousettus aegypticus, has been identified as the host for MARV
[4] while the very recently described Bombali ebolavirus (BOMV) and
LLOV genome sequences were discovered in samples of insectivorous
bats in Africa and Europe, respectively [2,5]. While the exact host of
ebolaviruses has not been confirmed yet, genetic and serological evi-
dence of ebolavirus infections have been detected in a few species of
fruit bats and most recently insectivorous bats [5–9]. Advances in virus
discovery techniques have also yielded detection of novel marburg- and
cuevaviruses in bats in China [10,11] thus expanding the known range
of filoviruses.
The largest Ebola outbreak to date took place in 2014–2016 in both
rural and urban areas of Guinea, Sierra Leone and Liberia in West
Africa. It was caused by the EBOV, with more than 28 000 reported
cases, including more than 11 000 deaths (World Health Organization,
WHO; http://www.who.int/csr/disease/ebola/en/). This epidemic
highlighted the need for rapid detection of EBOV for disease contain-
ment. In response, novel diagnostic tools have been developed for rapid
and safe identification of EBOV (reviewed in Clark et al. [12]). The
development of efficacious ring vaccination and new treatment mod-
alities further requires efficient diagnostics. Most recently, the WHO
reported a new epidemic of EBOV in the Democratic Republic of the
Congo (DRC) in May 2018, and an unrelated outbreak some 2500 km
away in DRC in July 2018 calling for swift response yet again.
Between the EBOV outbreaks, a smaller outbreak of MARV occurred
in Uganda in October 2017, emphasizing the need to develop pre-
paredness to diagnose all filoviruses. Whereas many protocols have
been developed recently for detection of EBOV, the detection methods
covering the whole range of filoviruses still rely largely on the protocol
by Panning et al. [13]. The discoveries of yet novel filoviruses [5]
further underline the need to update and improve the preparedness for
rapid and sensitive detection of filoviruses.
Nucleic acid testing is the gold standard for filovirus diagnostics due
to high viral loads that become detectable in just a few days after in-
fection [14]. Such diagnostic tools need to be set up both at the site of
the epidemic, and at sites of potential importation. The EBOV outbreak
in West Africa activated a broad laboratory response e.g. in Europe
[15], with modern molecular diagnostics vastly available for detection
of EBOV. For example, freeze-dried PCR reagents would ease the
transport and use of the assays in harsh field conditions at the site of
epidemic.
Critical steps in nucleic acid testing are biosafe sample preparation
and transport. Different protocols for the inactivation of ebolaviruses
have been investigated, such as Qiagen AVL buffer and the MagNa Pure
Lysis buffer (MPLB; Roche Life Science, Espoo, Finland). The protocol
for sampling directly into MPLB has been suggested [16] and this would
enable biosafe transport, which is challenging nowadays. Two widely
used inactivators are Triton™-X 100, which interferes with lipid mem-
branes, and lysis buffers containing guanidinium thiocyanate that lyse
cells and inhibit nuclease activities. Neither of these can alone in-
activate ebolaviruses, but parallel use of these two [e.g. Triton™-X 100
together with AVL buffer from Viral RNA mini kit (Qiagen) or MPLB
(Roche)] have been shown to fully inactivate ebolaviruses [16–18].
WHO has recommended the parallel usage of two different inactivation
reagents.
2. Objectives
Here we aimed to develop and evaluate a broad-range pan-filovirus
detection method allowing early identification of the causative agent of
a filovirus outbreak. We also evaluated the freeze-dried and liquid
formats, and possible effects that sample inactivation methods may
have on the sensitivity of the assay. Finally, the method was put to test
with a large panel of EVD outbreak patient samples.
3. Study design
3.1. Pan-filo L-RT-qPCR
Two different PCR reagents; Superscript® III Platinum® One-step
qRT-PCR System (Invitrogen, Carlsbad, CA, USA; later referred as the
Invitrogen assay) and lyophilized one-step RT-qPCR reagents (Thermo
Fisher Scientific, Massachusetts, USA; later referred as the Thermo-
lyophilized assay) were used with the same primers, probes, and viral
RNA panels.
A pan-filo L-RT-qPCR targeting the L gene was developed and
evaluated. For the assay, two separate reactions were carried out for
each sample in the same run.
In the first reaction, 160 nM FAM-labelled Filo1 and Filo2 probes
(adapted from Jääskeläinen et al. [19]; targeting ZEBOVs) in addition
to ZEBOV/MARV reverse primers [480 nM of 5ʼ-AATGCATCCAATTAA
AAACATTC-3ʼ [19], 240 nM of 5ʼ-AATGCATCCARTCRAATAAATTY-3ʼ]
and 240 nM ZEBOV/MARV forward primers [5ʼ-AACTGATTTAGAGAA
ATACAATCTTGC-3ʼ [19], 5ʼ-CTGATCTTGAGAAATACAACCTCGC-3ʼ,
5ʼ-ACTGATYTAGAGAAATACAAYCTYGC-3ʼ], and 160 nM VIC-labelled
Filo3 and Filo4 probes [VIC- TTT ACA CGR CAT TTC ATA GAC T-
MGBNFQ and VIC- ACT GTA ATC GAT GTT ATG GT-MGBNFQ; mainly
targeting MARVs] were used with final concentration of 2mM MgSO4.
In the second reaction, a final concentration of 240 nM of BDBV-RV
primer [5ʼ-AATGCATCCAATTGAATAAATTT-3ʼ], 240 nM SUDV-RV [5ʼ-
CATCCAATCAAAGACATTGC-3ʼ], 320 nM FILO-FW [5ʼ-ACMGACCTR-
GARAAATAYAACYTGGC-3ʼ] in addition to 160 nM FAM-labelled Filo5-
probe [FAM- ATG AGT TTA CAG CTC CAT T-MGBNFQ; mainly BDBVs]
and 160 nM VIC-labelled Filo6 probe [VIC- TCA TCA AAT ATT GCA
ACC AA-MGBNFQ; mainly targeting SUDVs] were used.
The Invitrogen assay in the Mx3005P qPCR System (Agilent
Technologies Finland Oy, Espoo, Finland) was initially used to optimize
the concentrations of the primers and probes. Both Invitrogen and
Thermo-lyophilized assays were further tested by screening of different
filoviruses, and to verify the specificity, and to test the PCR reagent
ability to tolerate the inhibition effect of Triton™-X 100 (Sigma-Aldrich,
Espoo, Finland), MPLB (Roche), and AVL lysis buffer (Qiagen, Hilden,
Germany). Finally, the limits of detection (LODs) were determined for
the Thermo-lyophilized assay.
The RT-qPCR running protocol for Invitrogen-liquid assay was
adapted from the EBOV assay described in Jääskeläinen et al. [19] and
7 μl of template was used, and the protocol for Thermo-lyophilized
assay 3.6 μl of template was used and the run was carried out as follows:
reverse transcription for 10min at 45 °C, PCR initial activation step for
10min at 95 °C followed by 50 cycles of denaturation for 15 s at 95 °C,
and annealing and extension for 70 s at 60 °C.
3.2. Viral controls
Quantified in vitro RNAs were produced using constructs for EBOV
and MARV L genes (described in Jääskeläinen et al. [19]), in addition to
synthetized L-gene constructs of SUDV and BDBV ebolaviruses (Gen-
eArt™ Plasmid Construction Service, Thermo Fischer Scientific). RNAs
from inactivated whole virus controls of EBOV/Guinea C05 and EBOV/
Mayinga, MARV/Angola, RAVV, SUDV/Boniface, BDBV/E76, TAFV/
Ivory Coast and RESTV were obtained from Public Health England
(PHE, Porton Down, Salisbury, UK). These viruses were cultivated in
Vero E6 cells, inactivated, and RNA extracted using QIAamp Viral RNA
Mini kit (Qiagen, Hilden, Germany) according to manufacturer's in-
struction.
3.3. Specificity and inhibition tests
For assessing specificity, EDTA-blood samples from 45 individuals
that were sent for routine human herpesvirus 6 nucleic acid testing
(later referred as HU-samples) in Helsinki University Hospital
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(HUSLAB, Helsinki, Finland; anonymous samples, research permit
TYH2017257), were extracted using MagNa Pure 96 automated system
and nucleic acid kits (MPLB lysis; Roche Life Science, Espoo, Finland),
and tested using the Invitrogen and Thermo-lyophilized assays. In ad-
dition, for testing other viral hemorrhagic fever agents, the RNAs from
inactivated whole virus controls of Lassa virus (strain Liberia; LASV),
Dengueviruses 1–4 (DENV1–4), Yellow fever virus (strain 17D; YFV),
Rift Valley fever virus (strain RKI; RVFV) and Crimean-Congo hemor-
rhagic virus (strain Hoti; CCHFV) were extracted using QIAamp Viral
RNA Mini kit (Qiagen) (Table 1).
For Triton™-X 100 (Sigma-Aldrich, Espoo, Finland) inhibition tests,
excess amount of Triton™-X 100 was added to EDTA-blood samples in
final volume of 10% in order to test any PCR inhibition effect due to the
reagent in both Invitrogen and Thermo-lyophilized assays. Triton-
treated (10min at room temperature) EDTA-blood samples were ex-
tracted using AVL and QIAamp Viral RNA Mini kit (Qiagen). In addi-
tion, EDTA-blood samples without extra Triton treatment were ex-
tracted using MPLB and MagNA Pure extraction system (Roche).
Different amounts of EBOV, MARV, SUDV or BDBV RNAs were spiked
in the extracted samples, and both Thermo-lyophilized and Invitrogen
assays were carried out (Fig. 1).
Table 1
Sample panels, materials and viruses used for validation of both liquid and lyophilized assay formats of the pan-filo L-RT-qPCR, and the results of the validation.
Panel/sample material Microbial agent No of samples/tests,
neg/pos
Pan-filo L-RT-qPCR assays: Results from Liquid and Lyophilized platforms
compared
neg for
FILO RNA
pos for
FILO RNA
neg for
FILO RNA
pos for
FILO RNA
Liq (Invitrogen) Lyo (Thermo) Liq (Invitrogen) Lyo (Thermo)
NEG:
Whole blooda
Negative sample panel 45 – 45/45 45/45 0/45 0/45
Total 45 – 45/45 45/45 0/45 0/45
NEG:
Virusesb
YFV (strains 17D) 3 – 3/3 3/3 0/3 0/3
DENV1 (RKI) 3 – 3/3 3/3 0/3 0/3
DENV2 (RKI) 3 – 3/3 3/3 0/3 0/3
DENV3 (RKI) 3 – 3/3 3/3 0/3 0/3
DENV4 (RKI) 3 – 3/3 3/3 0/3 0/3
LASV (strain Liberia,
RKI)
3 – 3/3 3/3 0/3 0/3
RVFV (strain RKI, RKI) 3 – 3/3 3/3 0/3 0/3
CCHFV (strain Hoti, RKI) 3 – 3/3 3/3 0/3 0/3
Total 24 – 24/24 24/24 0/24 0/24
All FILO negatives 69/69 (100%; 95CI 94.8–100%)
POS: Viruses/Viral RNAs ZEBOV (strain Mayinga,
PHE)
– 3 0/3 0/3 3/3 3/3
MARV (strain Angola) – 2 0/2 0/2 2/2 2/2
MARV (strain Ravn) – 2 0/2 0/2 2/2 2/2
SUDV strain Boniface – 2 0/2 0/2 2/2 2/2
BDBV strain E76 – 2 0/2 0/2 2/2 2/2
Taï Forest virus strain
Ivory Coast
– 2 0/2 0/2 2/2 2/2
Reston virus – 2 0/2 0/2 2/2 2/2
MARV L-gene RNA (HU) – 15 0/15 0/15 15/15 15/15
ZEBOV L-gene construct
RNA (HU)
– 15 0/15 0/15 15/15 15/15
Total – 45 0/45 0/45 45/45 45/45
POS:
38 viral controls tested using RealStar®
Filovirus RT-PCR Kitc and Invitrogen
assay
Virus Reference test: RealStar® Filovirus
5 parallel rxns, mean Ct (± SD)
Liq, Invitrogen
5 parallel rxns, mean Ct (± SD)
ZEBOV (strain Guinea,
PHE); 100 copies/rxn
5/5, Ct 30.3 (± 0.31) 5/5, Ct 35.6 (± 0.66)
50 copies/rxn 5/5, Ct 32.3, (± 2.7) 4/5, Ct 36.2 (± 0.9)
25 copies/rxn 1/5, Ct 34.3 (ND) 1/5, Ct 36.1 (ND)
Total ZEBOV 11/15 10/15
SUDV L-gene (GeneArt),
1500 copies/rxn
5/5, Ct 31.3 (± 3.5) 5/5, Ct 38.3 (± 1.3)
150 copies/rxn 2/5, Ct 33.7 (± 3.8) 1/5, Ct 38.8 (ND)
15 copies/rxn 0/5 0/5
Total SUDV 7/15 6/15
BDBV L-gene (GeneArt)d,
1250; 625; 125 copies/
rxn
1250: Ct 31.4 (ND);
625: Ct 32.0 (ND);
125:Ct 35.4 (ND)
1250: Ct 33.4 (ND),
625: Ct 36.5 (ND),
125: Ct 36.3 (ND)
62.5 copies/rxn 1/5, Ct 30 (ND) 4/5, Ct 38.1 (± 1.4)
Total BDBV 4/8 7/8
Altogether 22/38 23/38
POS, positive; NEG, negative; FILO, filoviruses; rxn, reaction; ND, not determined; ZEBOV, Zaire ebolavirus; MARV, Marburg virus; BDBV, Bundibugyo virus; SUDV,
Sudan ebolavirus; HU, University of Helsinki; PHE, Public Health England; RKI, Robert Koch Institute; DENV, denguevirus; LASV, Lassa virus; YFV, yellow fever
virus; CCHFV, Crimean-Congo Hemorrhagic virus; RVFV, Rift-Valley Fever virus.
a EDTA-Blood samples (Helsinki University Hospital, HUSLAB, Finland).
b RNA extractions from inactivated virus cultivations kindly provided by Prof. Niedrig (Robert Koch Institute, Germany).
c RealStar® Filovirus Screen RT-PCR Kit (altona Diagnostics GmbH, Hamburg, Germany). Only liquid phase Invitrogen pan-filo L RT-qPCR assay was carried out
parallel with RealStar® Filovirus Screen RT-PCR Kit.
d Only one reaction was carried out.
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3.4. Sensitivity
Sensitivity of the pan-filo L-RT-qPCR was tested using the Thermo-
lyophilized assay and serial dilutions of quantified RNA transcripts
(Qubit, Thermo Fisher Scientific) of EBOV, MARV, SUDV and BDBV L-
gene, and TAFV (PHE, quantified). Five parallel reactions and Probit
Regression (SPSS, IBM) were used to determine LODs. The Invitrogen
assay was tested in parallel with the WHO-approved RealStar® Filovirus
RT-PCR Kit (Altona Diagnostics GmbH, Hamburg, Germany) using
ZEBOV strain Guinea (range 5–1000 genome copies/PCR reaction;
PHE), SUDV L-gene RNA (range 7-1.5E6 genome copies/PCR reaction)
and BDBV L-gene RNA (range 13-1.25E6 genome copies/PCR reaction)
(Table 1). In addition, whole virus controls (Table 1, PHE) were tested
to screen different filovirus targets.
3.5. Screening of ebola patient samples
Samples were collected in Guinea between December 2014 and May
2015 as part of the Institute Pasteur de Dakar (IPD) diagnostics activ-
ities of suspected EVD cases (under an emergency response mandate
from the government of Guinea and WHO, ref 0235/14/GUI/CPC; all
patients agreed to be tested for Ebola virus infection and leftover
samples to be used for further investigations). Suspect Ebola patients
were defined as any person with recent or past sudden onset of fever
and having been in contact with a suspected, probable or confirmed
case of EVD, or any person with sudden onset of fever and at least three
of the following symptoms: headaches, anorexia/loss of appetite, le-
thargy, myalgia, arthralgia, breathing difficulties, or any person with
inexplicable bleeding. Eighty-three serum samples from acute cases
were extracted using QIAamp Viral RNA Mini kit (Qiagen) according to
manufacturer´s instructions in IPD, Senegal. These were all EBOV nu-
cleic acid positive using the reference EBOV NP-RT-qPCR (Weidmann
et al. [20]; using modified forward primer of 5ʼ-ATGATGGARGCTAC-
GGCG-3ʼ and probe 5ʼ-CARAGTTACTCGGAAAACGGCAT) with viral
loads ranging from 5 RNA copies to 5.5 million RNA copies per reac-
tion. In IPD, the pan-filo L-RT-qPCR and EBOV NP-RT-qPCR were car-
ried out in parallel using QuantiTect® Probe RT-PCR kit (Qiagen) and
5 μl of template for performance comparison.
4. Results
Both Invitrogen and Thermo-lyophilized pan-filo L-RT-qPCR assays
tested negative for HU-samples (N=45), as well as for LASV, DENV1–4,
YFV, RVFV and CCHFV, indicating analytical specificity of 100% (95CI:
94.8–100%; Table 1). In addition, both assays detected EBOV/Guinea
C05, EBOV/Mayinga, MARV/Angola, RAVV, SUDV/Boniface, BDBV/
E76, TAFV/Ivory Coast and RESTV (Table 1).
The LODs (SPSS, Probit, 95CI) for Thermo-lyophilized assay were
9.9 copies/PCR reaction for MARV, 9.4 for EBOV, 65 for BDBV, 1151
for SUDV and 289 for TAFV (PHE).
The Invitrogen pan-filo L-RT-qPCR assay was as good as the
RealStar® Filovirus Screen RT-PCR Kit for EBOV, however, for BDBV
and SUDV samples there were minor differences (Table 1).
Triton™-X 100 (Sigma-Aldrich), AVL (Qiagen) or MPLB (Roche) did
not interfere the Invitrogen or Thermo-lyophilized one-step assays
(Fig. 1).
All of the patient samples tested (83) from IPD (Senegal) were po-
sitive for EBOV nucleic acids using our pan-filo L-RT-qPCR assay and
EBOV NP-RT-qPCR (Fig. 2) indicating 100% analytical sensitivity. The
LOD for EBOV NP-RT-qPCR was 4 copies/PCR reaction (tested in Uni-
versity of Helsinki; SPSS, Probit, 95CI).
5. Discussion
Filoviruses were first isolated more than 50 years ago, and out-
breaks with high mortality have subsequently been caused by four
viruses, MARV (9 times) SUDV (5 times), BDBV (twice) and EBOV (14
times) (WHO). For containing and restricting the epidemics, including
establishing control measures and therapeutics, accessible, rapid and
reliable diagnostic tests are essential. IgM and IgG detection assays are
used to confirm resolved disease or to diagnostically monitor samples of
cases beyond the diagnostic window for molecular detection. While
rapid antigen detection tests with varying sensitivity and specificity
have been developed for EBOV detection [21,22], nucleic acid detec-
tion remains the cornerstone of diagnostics. It is a challenge to find
simple protocols, particularly primer and probe sequences applicable to
all pathogenic filoviruses, yet tests covering all filoviruses would be
essential in early identification of outbreaks as well as occasional cases
in endemic regions or travelers. Adding such a test and its evaluation is
what we report here. However, in future, the lyophilized protocol
would benefit from lyophilized primers and probes in mastermixes
making the protocol more suitable for field conditions.
After the West African EBOV epidemic, a variety of methods, in-
activation protocols and handling procedures have been studied
Fig. 1. (a) and (b) Comparing the performance of the pan-filo L-RT-qPCR using
Thermo-lyophilized and Invitrogen-liquid assays for potential inhibitory effects
of different reagents and inactivation methods [Fig. 1a.,Triton™-X 100 treat-
ment (Triton) or Fig. 1b. Magna Pure Lysis buffer (MPLB)].
Ex, 10−x (E1=10−1, E2= 10−2…) dilution, single replicate; MARV L, L-gene
construct of Marburg virus; ZEBOV Guinea, RNA extract of Zaire ebolavirus;
BDBV L, L-gene construct of Bundibugyo virus; SUDV L, L-gene construct of
Sudan ebolavirus; negat, negative.
Triton: EDTA-blood Triton™-X 100 treated and extracted using Qiagen kit,
spiked with filoviral RNA.
MPLB: EDTA-blood, Magna Pure LC extracted, using Magna Pure Lysis buffer,
spiked with filoviral RNA.
Over Ct 40 results are not considered real positive until confirmed by another
test if used in diagnosis of filoviral disease in clinical settings. Here Ct-values
are listed due to the comparison purposes.
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[16–18]. Most of the detection methods, however, have been based on
the detection of only EBOV nucleic acids, and this limitation can cost
time for diagnosis of other filoviruses. At the moment there is only one
commercial pan-filovirus kit (RealStar® Filovirus Screen RT-PCR Kit)
approved by WHO that also detects MARV, others still aim to detect
EBOV antigen or nucleic acids (WHO; http://www.who.int/medicines/
ebola-treatment/emp_ebola_diagnostics/en/). These WHO-approved
tests include Liferiver™ Ebola Virus (EBOV) Real Time RT-PCR kit
(Shanghai ZJ BioTech Co., Ltd) which can be used for detection EBOV,
SUDV, TAFV, BDBV, and Xpert® Ebola Test (Cepheid AB, Sweden),
FilmArray™ Biothreat-E (BioFire Defence LLC, USA) which both only
detect EBOV.
The 2-well pan-filo L-RT-qPCR assay described here detected all the
tested strains of MARV, EBOV, BDBV, SUDV, TAFV, as well as RESTV.
In addition, we were able to validate the pan-filo L-RT-qPCR assay with
clinical samples from the West-African EBOV outbreak with excellent
performance. Overall, the assay achieved better performance for EBOV
and MARV than rest of the tested targets, but was still at the same level
as WHO-approved RealStar® Filovirus Screen RT-PCR kit. With this in
mind, it´s recommended to test several samples from patient suspected
for VHF to avoid false negative results at the early onset of disease.
The specificity was 100%, and the lyophilized or liquid assays were
not affected by common chemical inactivation reagents, i.e. MPLB, AVL
or Triton™-X 100. These results are in line with Rosenstierne et al. [16]
who tested MPLB and AVL buffers.
Based on the sequences, the pan-filo L-RT-qPCR primers and probes
are not a perfect match for BOMV (MF319185; forward primer 4, re-
verse 2, and VIC-probe 3 mismatches) or other bat-related filoviruses in
GenBank (National Center for Biotechnology Information, USA).
However, when screening Kenyan bat samples, with the pan-filo L-RT-
qPCR we detected one sample positive for filovirus. The bat-related
filovirus was later sequenced and identified as BOMV [23].
We conclude that the developed assays, both lyophilized and liquid
phase, can be used effectively to screen samples from patients suspected
for any known filoviral hemorrhagic fever, and both marburg and
ebolaviruses can be detected.
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